The cancer genetics testing provider acquired its new business unit from GE Healthcare.
By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.
NeoGenomics and GE Healthcare will also collaborate on a bioinformatics initiative for personalized oncology.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
The licenses provide non-exclusive access to the IP for research applications.
General Electric has been awarded
Originally published Oct. 3.
NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.
Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013
GE Healthcare this week launched the illustra Single Cell GenomiPhi DNA amplification kit from.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.